Because of the potential risk of toxicity from the large amount of the excipient, propylene glycol, contained in AGENERASE Oral Solution, that formulation is contraindicated in infants and children below the age of 4 years and certain other patient populations and should be used with caution in others. Consult the complete prescribing information for AGENERASE Oral Solution for full information.
PATIENT INFORMATION INCLUDED
AGENERASE (amprenavir) is an inhibitor of the human immunodeficiency virus (HIV) protease.
AGENERASE (amprenavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The following points should be considered when initiating therapy with AGENERASE:
In a study of NRTI-experienced, protease inhibitor-naive patients, AGENERASE was found to be significantly less effective than indinavir.
Mild to moderate gastrointestinal adverse events led to discontinuation of AGENERASE primarily during the first 12 weeks of therapy (ADVERSE REACTIONS).
There are no data on response to therapy with AGENERASE in protease inhibitor-experienced patients.
Media Articles Related to Agenerase (Amprenavir)
New HIV infections stagnating at 2.5 million a year worldwide
Source: HIV / AIDS News From Medical News Today [2016.07.19]
Between 2005 and 2015, rate of new HIV infections increased in 74 countries.
Increasing rates of medical male circumcision, female ART coverage linked with lower rates of HIV infection among men
Source: HIV / AIDS News From Medical News Today [2016.07.13]
In a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue, Xiangrong Kong, Ph.D.
Study finds better definition of homelessness may help minimize HIV risk
Source: HIV / AIDS News From Medical News Today [2016.08.23]
Being homeless puts people at greater risk of HIV infection than those with stable housing, but targeting services to reduce risk behaviors is often complicated by fuzzy definitions of homelessness.
Maternal HIV status may disrupt normal microbiome development in uninfected infants
Source: HIV / AIDS News From Medical News Today [2016.07.28]
A study led by researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) suggests that maternal HIV infection influences the microbiome of their HIV-uninfected infants.
Published Studies Related to Agenerase (Amprenavir)
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [2010.03]
Objective An open-label, three-period pharmacokinetic study was conducted to investigate the drug interaction potential between fosamprenavir (FPV) and tenofovir disoproxil fumarate (TDF). Methods Thirty-six healthy subjects received TDF 300 mg once daily (qd) for 7 days (period 1), and then were randomized to 14 days of either FPV 1400 mg twice daily (bid) or FPV/ritonavir (RTV) 700/100 mg bid alone or with TDF (period 2)...
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [2009.08]
STUDY OBJECTIVE: To quantify the pharmacokinetics of amprenavir and atazanavir (administered as the prodrug fosamprenavir) alone and in combination in human immunodeficiency virus (HIV)-negative subjects... CONCLUSION: Atazanavir 400 mg/day plus fosamprenavir 1400 mg/day significantly decreased concentrations of atazanavir compared with standard dosing regimens of each drug alone. This dosing scheme is not a recommended combination of dual, fully active protease inhibitors.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. [2009.08]
BACKGROUND: APV102002 was an open-label study comparing a dual-boosted HIV-1 protease inhibitor (PI) [fosamprenavir/lopinavir/ritonavir (FPV/LPV/RTV; 1400 mg/533 mg/133 mg twice daily)] and a high dose of FPV/RTV 1400 mg/100 mg twice daily (HD-FPV/RTV) versus the standard FPV/RTV 700 mg/100 mg twice-daily (STD-FPV/RTV) regimen for 24 weeks... CONCLUSIONS: While the strategies of higher dose FPV/RTV and dual FPV/LPV/RTV were relevant at the time of study initiation, new therapies for antiretroviral-experienced patients make such strategies of limited interest. In addition, this study failed to demonstrate antiviral superiority of the HD-FPV/RTV or FPV/LPV/RTV regimen over the STD-FPV/RTV twice-daily regimen in highly treatment-experienced patients.
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]
The effect of tenofovir disoproxil fumarate (TDF) in combination with two boosted fosamprenavir regimens on amprenavir pharmacokinetic parameters was assessed in this prospective phase I crossover study with 30 healthy volunteers.
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. [2006.08]
Previous investigations have shown a significant negative two-way drug interaction between fosamprenavir (FPV) and lopinavir/ritonavir (LPV/RTV) in both human immunodeficiency virus (HIV)-infected patients and seronegative volunteers. This randomized, nonblinded, three-way crossover study of HIV-seronegative adult volunteers investigated dose separation and increased doses of RTV as a means to overcome the interaction between FPV and LPV/RTV...
Clinical Trials Related to Agenerase (Amprenavir)
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment [Active, not recruiting]
The purpose of this study is to determine if treatment with an anti-HIV drug containing
ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who
have failed an anti-HIV drug treatment containing nelfinavir.
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults [Terminated]
Study to determine the effects of 28 days of nevirapine treatment on the steady-state
pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics
of nevirapine in combination with amprenavir and abacavir compared to historical controls
treated with nevirapine but without amprenavir or abacavir. In addition safety/tolerance of
nevirapine, amprenavir and abacavir was to be assessed based on adverse events and clinical
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment [Active, not recruiting]
The purpose of this study is to see how effective and safe it is to give 1 of the 3
following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine
(3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir [Completed]
To determine the proportion of patients treated with amprenavir, zidovudine (ZDV), stavudine
(D4T) and lamivudine (3TC) whose HIV-1 RNA level remains below the level of detection during
96 weeks of therapy. To determine the proportion of patients treated with indinavir (IDV),
nevirapine (NVP), 3TC, and d4T whose HIV-1 RNA level decreases and then remains below the
level of detection, during the 96-week therapy period. To determine the viral effects,
safety, tolerability, and pharmacokinetics of amprenavir in combination with zidovudine,
stavudine, and lamivudine. [AS PER AMENDMENT 2/27/98: To determine the proportion of
patients with undetectable plasma HIV RNA, by treatment and baseline RNA cohort (either
detectable or undetectable). To determine the durability of these regimens by estimating the
distribution of time to loss of virologic suppression (or equivalently, time to virologic
failure), by treatment and baseline RNA cohort.] This study allows patients who have
successfully participated in ACTG 347 or other trials involving amprenavir to continue
treatment with amprenavir, ZDV, d4T, and 3TC. Additionally, this study provides patients
whose HIV-1 RNA was not reduced to undetectable levels or who had a significant increase in
plasma levels ("treatment failures") the opportunity to change to a potentially more active
regimen that includes indinavir, nevirapine, lamivudine, and stavudine.
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients [Completed]
The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to
determine the number of people whose HIV blood levels decrease to 200 copies/ml or less
while on the treatment. This study evaluates the safety of these drug combinations, which
include an experimental protease inhibitor (PI), amprenavir.
Despite the success that many patients have had with PI treatment regimens, there is still a
possibility that patients receiving PIs may continue to have high HIV blood levels. Because
of this possibility, alternative drug combinations containing PIs are being studied. It
appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in
patients with prior PI treatment experience.
Page last updated: 2016-08-23